All News
STAT+: Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion
Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.
Read MoreWeight loss jabs may achieve less drastic results outside trials, study suggests
Patients in real world shed less weight than in clinical settings and may benefit more from bariatric surgeryPeople using weight loss jabs shed far fewer pounds in the real world than in clinical tria
Read MoreSTAT+: Isomorphic Labs sets up U.S. presence, with an eye on clinical trials
As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge.
Read MoreIndia’s moment in the fight against blood cancer
Amit Mookim, CEO, Immuneel Therapeutics, highlights the burden of blood cancer in India and how government policies and insurance regulatory bodies must evolve to enhance access and affordability of a
Read MoreQuadria Group takes control of HealthQuad for launching Fund III with a corpus of $300 mn
As part of this next chapter, Quadria group, through Dr Amit Varma, Abrar Mir, and Sunil Thakur will assume full ownership and control of the platform following its separation from KOIS
Read MoreThe Price You Pay for an Obamacare Plan Could Surge Next Year
An estimated 4 million Americans will lose health insurance over the next decade if Congress doesn’t extend enhanced subsidies for Affordable Care Act marketplace coverage, which expire at the end o
Read More‘MAGA’ Backers Like Trump’s ‘Big Beautiful Bill’ — Until They Learn of Health Consequences
A new poll finds that most adults oppose the GOP bill that would extend many of President Donald Trump’s tax cuts while reducing spending on domestic programs including Medicaid.
Read MoreSTAT+: Nabla raises $70 million as market for AI tools to help doctors heats up
AI developer Nabla has raised $70 million as the company looks to expand the capabilities of its software that automates clinical documentation.
Read MoreOpinion: Obesity drugs don’t just offer weight loss. They give patients agency
Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.
Read MoreSTAT+: China, where obesity levels are low, becomes hotbed for weight loss drug trials
China is a one of the most important regions for the booming obesity market, thanks to government incentives and changing demographics.
Read More